ACM
BMY icon

Altrius Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Altrius Capital Management’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-91,834
Closed -$5.6M – 86
2025
Q1 		$5.6M Sell
91,834
-3,217
-3% -$188K 1.36% 31
2024
Q4 		$5.38M Sell
95,051
-2,611
-3% -$146K 1.45% 29
2024
Q3 		$5.05M Buy
97,662
+620
+0.6% +$29.1K 1.27% 40
2024
Q2 		$4.03M Buy
97,042
+20,100
+26% +$899K 1.06% 58
2024
Q1 		$4.17M Buy
76,942
+8,110
+12% +$413K 1.05% 55
2023
Q4 		$3.53M Buy
68,832
+14,690
+27% +$771K 0.98% 63
2023
Q3 		$3.14M Buy
54,142
+7,533
+16% +$462K 0.93% 64
2023
Q2 		$2.98M Buy
46,609
+1,785
+4% +$120K 0.88% 67
2023
Q1 		$3.11M Buy
44,824
+3,108
+7% +$219K 0.95% 62
2022
Q4 		$3M Sell
41,716
-1,325
-3% -$99.9K 0.94% 63
2022
Q3 		$3.06M Sell
43,041
-24,998
-37% -$1.81M 1.17% 32
2022
Q2 		$5.24M Buy
+68,039
New +$5.18M 1.7% 7

Other funds holding BMY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Altrius Capital Management's BMY Position: Q2 2025 in Review

Altrius Capital Management sold out of Bristol-Myers Squibb (BMY) in Q2 2025, closing a stake of 91,834 shares — an estimated $5.6M sold.

Altrius Capital Management first reported a position in BMY in Q2 2022 and held it in 12 quarters. The position peaked at $5.6M in Q1 2025. 2,297 funds tracked by Wall St. Rank hold BMY as of Q2 2025.

  • Altrius Capital Management reported no remaining Bristol-Myers Squibb position as of Q2 2025 after selling out during the quarter.
  • Altrius Capital Management sold 91,834 Bristol-Myers Squibb shares in Q2 2025, an estimated $5.6M.
  • Altrius Capital Management first reported a position in Bristol-Myers Squibb in Q2 2022 and held it in 12 quarters.
  • Altrius Capital Management's Bristol-Myers Squibb position peaked at $5.6M in Q1 2025.
  • 2,297 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2025.

Based on Altrius Capital Management's 13F filing for Q2 2025, filed 6 Aug 2025.